To aid in the identification of patients eligible for treatment and to monitor response to therapy, DiaCarta offers QClamp® KRAS Mutation Detection Test in plasma and Formalin-Fixed Paraffin-Embedded (FFPE) samples which can lead to improved outcomes in cancer patients. The QClamp® KRAS Mutation Detection Test is an in vitro diagnostic real-time qualitative PCR assay for the detection of somatic mutations in and near codons 12 and 13 in Exon 2, codons 59 and 61 in Exon 3, and codons 117 and 146 in Exon 4 in the human KRAS gene, using purified DNA extracted from FFPE or plasma.
Powered by XNA technology, the QClamp® KRAS Mutation Detection Test has achieved a much higher analytical sensitivity compared to other commercial qPCR kits and other cancer gene mutation detection methods. QClamp® KRAS Mutation Detection Test is able to detect reliably 0.1% to 0.5% mutant DNA out of wild-type DNA for targeted mutations, providing lower detection limit compared with competition due to a strict enrichment of mutant sequences while suppressing amplification of wild-type sequences.
QClamp® KRAS Mutation Detection Test is CE/IVD-certified.
Advantages of QClamp® KRAS Mutation Detection Test
Detect reliably 0.1% to 0.5% VAF mutant DNA out of wild-type DNA for targeted mutations
plasma and FFPE samples
LOW INPUT DNA
Minimum 5ng input DNA per reaction. Less than 2 tubes of blood (10mL each) needed for cfDNA
Covering all relevant somatic mutations in 6 codons of
Less than 4 hours of
assay run time
Validated on the most common
qPCR machines with minimized variability
KRAS Mutation and Cancer
KRAS: the Most Frequently Mutated Oncogene in Cancer
The most common cancer gene mutations, Kirsten rat sarcoma viral oncogene (KRAS) mutations, are found in several cancers including pancreatic (80 to 90%), colorectal (25 to 60%), lung (25 to 60%) cancers, and associated with poor prognosis. KRAS mutations may lead to abnormal growth
KRAS as an Important Biomarker for Targeted Therapy
The epidermal growth factor receptor (EGFR), which is overexpressed in metastatic colorectal cancer (
Recent Clinical Study
For patients who receive treatment while having wild-type KRAS and later become drug-resistant, about fifty
Streamlined Workflow for QClamp® KRAS Mutation Detection Tests
Step 1: DNA Isolation & Quantification
Extract DNA from FFPE or plasma using a commercial DNA extraction kit followed by measuring the concentration using fluorometric analysis
Step 2: set up qpcr
Mix the assay reagents, load into PCR plate, add controls and extracted DNA ~ 30-60 minutes
Step 3: Amplification parameters
Enter amplification parameters on
qPCR instrument, load PCR plate
and start the run ~ 2.5 hours
Step 4: Data analysis
Determine the presence or absence
of mutations according to the Cq
value cutoffs ~ 15 minutes
CE/IVD catalog Number: DC-10-3010;
Research-use-only (RUO) catalog number: DC-10-3010R
Codons 12, 13, 59, 61, 117 and 146
In vitro diagnostic Use (CE/IVD) or for research use
Plasma and FFPE
Roche LightCycler® 480, Bio-Rad CFX384 and ABI QuantStudio 5
Less than 4 hours
Stable for 12 months at -25 ℃ to -15 ℃
Most frequent KRAS mutations detected by QClamp® KRAS Mutation Detection Test
|Exon||Amino Acid Change||Nucleotide change||Cosmic No.|
|Q61>H||c.183A>C & c.183A>T||554/555|
|K117>N||c.351A>C & c.351A>T||19940/28519|
Analytical sensitivity in plasma: Detects as low as 0.5% VAF mutant DNA in a 5ng input
cfDNA extracted from plasma of a colorectal cancer patient with known KRAS G12D mutation was diluted in 5ng/μl of wild-type cfDNA. VAF of the sample was verified by Next-Generation Sequencing (NGS). The KRAS c12 assay is able to detect as low as 7-8 KRAS G12D mutant gene copies (0.5% VAF) in the background of wild-type cfDNA.
Analytical sensitivity in FFPE: Detects as low as 0.1% VAF mutant DNA in a 5ng input
DNA extracted from FFPE of a colorectal cancer patient with known KRAS G12D mutation was diluted in 5ng/μl of wild-type FFPE DNA. VAF of the sample was verified by NGS. The KRAS c12 assay is able to detect as low as 1.5 KRAS G12D mutant gene copies (0.1% VAF) in the background of wild-type FFPE DNA.
For products that are in stock, DiaCarta will arrange shipment in 1-3 days. For products that are on backorder, DiaCarta will arrange shipment in 3-5 weeks.
Intended Use: QClamp® KRAS Mutation Detection Test is CE/IVD-certified. For the outside USA, this product is available for diagnostic use (CE/IVD) and research use (RUO). For the USA, this product is provided for research use only (RUO) and not for diagnostic use. DiaCarta ships CE/IVD version to the outside USA and ships RUO version to the USA. Please call 1-800-246-8878 or email email@example.com if you have questions or specific needs.
Shipping Condition: QClamp® KRAS Mutation Detection Test will be shipped with dry ice. For domestic shipment, DiaCarta provides overnight delivery through FedEx Domestic Overnight Shipping Service. For international shipment, DiaCarta provides 3-7 days in transit through FedEx International Priority Shipping Service. Please contact DiaCarta if you prefer to use your own shipping carrier.